208 related articles for article (PubMed ID: 26364942)
1. Progress in the development of fatty acid synthase inhibitors as anticancer targets.
Mullen GE; Yet L
Bioorg Med Chem Lett; 2015 Oct; 25(20):4363-9. PubMed ID: 26364942
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid synthase inhibition induces differential expression of genes involved in apoptosis and cell proliferation in ocular cancer cells.
Deepa PR; Vandhana S; Krishnakumar S
Nutr Cancer; 2013; 65(2):311-6. PubMed ID: 23441619
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?
Lupu R; Menendez JA
Curr Pharm Biotechnol; 2006 Dec; 7(6):483-93. PubMed ID: 17168665
[TBL] [Abstract][Full Text] [Related]
4. Galloyl esters of trans-stilbenes are inhibitors of FASN with anticancer activity on non-small cell lung cancer cells.
Tan YJ; Ali A; Tee SY; Teo JT; Xi Y; Go ML; Lam Y
Eur J Med Chem; 2019 Nov; 182():111597. PubMed ID: 31422225
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of fatty acid synthase in human gliomas correlates with the WHO tumor grade and inhibition with Orlistat reduces cell viability and triggers apoptosis.
Grube S; Dünisch P; Freitag D; Klausnitzer M; Sakr Y; Walter J; Kalff R; Ewald C
J Neurooncol; 2014 Jun; 118(2):277-287. PubMed ID: 24789255
[TBL] [Abstract][Full Text] [Related]
6. Pyridine derivatives as anticancer lead compounds with Fatty Acid Synthase as the target: An in silico-guided in vitro study.
Amrutha NA; Archana PR; Mohan SG; Anto RJ; Sadasivan C
J Cell Biochem; 2019 Oct; 120(10):16643-16657. PubMed ID: 31095793
[TBL] [Abstract][Full Text] [Related]
7. Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer.
Corominas-Faja B; Vellon L; Cuyàs E; Buxó M; Martin-Castillo B; Serra D; García J; Lupu R; Menendez JA
Histol Histopathol; 2017 Jul; 32(7):687-698. PubMed ID: 27714708
[TBL] [Abstract][Full Text] [Related]
8. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy.
Schcolnik-Cabrera A; Chávez-Blanco A; Domínguez-Gómez G; Taja-Chayeb L; Morales-Barcenas R; Trejo-Becerril C; Perez-Cardenas E; Gonzalez-Fierro A; Dueñas-González A
Expert Opin Investig Drugs; 2018 May; 27(5):475-489. PubMed ID: 29723075
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy.
Lu T; Schubert C; Cummings MD; Bignan G; Connolly PJ; Smans K; Ludovici D; Parker MH; Meyer C; Rocaboy C; Alexander R; Grasberger B; De Breucker S; Esser N; Fraiponts E; Gilissen R; Janssens B; Peeters D; Van Nuffel L; Vermeulen P; Bischoff J; Meerpoel L
Bioorg Med Chem Lett; 2018 Jul; 28(12):2159-2164. PubMed ID: 29779975
[TBL] [Abstract][Full Text] [Related]
10. Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer.
Grunt TW; Slany A; Semkova M; Colomer R; López-Rodríguez ML; Wuczkowski M; Wagner R; Gerner C; Stübiger G
Sci Rep; 2020 Sep; 10(1):14877. PubMed ID: 32913236
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase.
Wang CJ; Li D; Danielson JA; Zhang EH; Dong Z; Miller KD; Li L; Zhang JT; Liu JY
Cancer Lett; 2021 Jul; 509():1-12. PubMed ID: 33813001
[TBL] [Abstract][Full Text] [Related]
12. Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells.
Veigel D; Wagner R; Stübiger G; Wuczkowski M; Filipits M; Horvat R; Benhamú B; López-Rodríguez ML; Leisser A; Valent P; Grusch M; Hegardt FG; García J; Serra D; Auersperg N; Colomer R; Grunt TW
Int J Cancer; 2015 May; 136(9):2078-90. PubMed ID: 25302649
[TBL] [Abstract][Full Text] [Related]
13. Fatty Acid Inhibition Sensitizes Androgen-Dependent and -Independent Prostate Cancer to Radiotherapy via FASN/NF-κB Pathway.
Chuang HY; Lee YP; Lin WC; Lin YH; Hwang JJ
Sci Rep; 2019 Sep; 9(1):13284. PubMed ID: 31527721
[TBL] [Abstract][Full Text] [Related]
14. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer.
Sadowski MC; Pouwer RH; Gunter JH; Lubik AA; Quinn RJ; Nelson CC
Oncotarget; 2014 Oct; 5(19):9362-81. PubMed ID: 25313139
[TBL] [Abstract][Full Text] [Related]
15. G protein-coupled estrogen receptor mediates the up-regulation of fatty acid synthase induced by 17β-estradiol in cancer cells and cancer-associated fibroblasts.
Santolla MF; Lappano R; De Marco P; Pupo M; Vivacqua A; Sisci D; Abonante S; Iacopetta D; Cappello AR; Dolce V; Maggiolini M
J Biol Chem; 2012 Dec; 287(52):43234-45. PubMed ID: 23135268
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of fatty-acid synthase suppresses P-AKT and induces apoptosis in bladder cancer.
Jiang B; Li EH; Lu YY; Jiang Q; Cui D; Jing YF; Xia SJ
Urology; 2012 Aug; 80(2):484.e9-15. PubMed ID: 22554590
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in the Development of Fatty Acid Synthase Inhibitors as Anticancer Agents.
Singh S; Karthikeyan C; Moorthy NSHN
Mini Rev Med Chem; 2020; 20(18):1820-1837. PubMed ID: 32781957
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression.
Ventura R; Mordec K; Waszczuk J; Wang Z; Lai J; Fridlib M; Buckley D; Kemble G; Heuer TS
EBioMedicine; 2015 Aug; 2(8):808-24. PubMed ID: 26425687
[TBL] [Abstract][Full Text] [Related]
19. Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer.
Alwarawrah Y; Hughes P; Loiselle D; Carlson DA; Darr DB; Jordan JL; Xiong J; Hunter LM; Dubois LG; Thompson JW; Kulkarni MM; Ratcliff AN; Kwiek JJ; Haystead TA
Cell Chem Biol; 2016 Jun; 23(6):678-88. PubMed ID: 27265747
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic and toxicologic evaluation of anti-lipogenic agents in cancer cells compared with non-neoplastic cells.
Deepa PR; Vandhana S; Jayanthi U; Krishnakumar S
Basic Clin Pharmacol Toxicol; 2012 Jun; 110(6):494-503. PubMed ID: 22151915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
